 | This article needs additional citations for verification. (August 2022) |
 | |
| Company type | Public |
|---|---|
| Nasdaq: APRI | |
| Industry | Biopharmaceutical |
| Founded | 1987 |
| Headquarters | San Diego, California, United States |
Key people | Richard Pascoe (CEO) Brian Dorsey (iSVP & Chief Development Officer) Barbara Troupin, MD, MBA (SVP & Chief Medical Officer) |
| Products | Vitaros, Fispemifene, RayVa, Femprox |
| Revenue | US$ 7.4 million (First Nine Months 2014) |
Number of employees | 120 (2012) |
| Website | [1] |
Apricus Biosciences, Inc. is a San Diego–based biopharmaceutical company advancing innovative medicines in urology and rheumatology.
Apricus Biosciences' first product, Vitaros®, has been approved in Europe and Canada for the treatment of erectile dysfunction[1] Other compounds in development include: low testosterone, rheumatology, sexual dysfunction, pain,[2]
- ^ Bujdos, Brian (16 November 2010). "New Topical Erectile Dysfunction Drug Vitaros Approved in Canada; Approved Topical Drug Testim Proves Helpful for Erectile Dysfunction". Archived from the original on 13 May 2011. Retrieved 7 April 2011.
- ^ "Apricus SEC Report". SEC. Retrieved 6 April 2011.